This research study is evaluating the effectiveness and safety of infliximab therapy compared
with steroids in the treatment of ipilimumab-induced colitis in patients with III/IV
melanoma.
Pembrolizumab + Infliximab for Metastatic Melanoma
Not yet recruiting
Massachusetts Institute of Technology
Phase 2
2022-01-01
The purpose of this research is to test the safety and effectiveness of the investigational
combination of pembrolizumab and infliximab in treating metastatic melanoma.
Pembrolizumab + Infliximab for Metastatic Melanoma
Not yet recruiting
Massachusetts General Hospital
Phase 2
2022-01-01
The purpose of this research is to test the safety and effectiveness of the investigational
combination of pembrolizumab and infliximab in treating metastatic melanoma.
Precise Infliximab Exposure and Pharmacodynamic Control
Not yet recruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2/Phase 3
2023-02-01
Approximately 3 million people in the United States are living with inflammatory bowel
disease, which includes Crohn's Disease (CD). There are limited treatment options approved
for use in children and adults with Crohn's disease. Physicians need better ways to inform
decisions on treatment.
The main reason for this research study is to determine if a computer program that calculates
an individualized dose based on a patient's blood testing results (precision dosing) can
better achieve the best possible response to infliximab compared to standard dosing
(conventional dosing).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.